

## **Consent to certain actions for the purposes of the Initial Enforcement Order made by the Competition and Markets Authority (CMA) on 1 April 2016**

### **Completed acquisition by AAH Pharmaceuticals Limited (AAH) of Medical Advisory Services For Travellers Abroad Limited and Sangers (Northern Ireland) Limited (MASTA-Sangers)**

We refer to [redacted] emails of 28 April 2016 and 12 May 2016 requesting that the CMA consents to a derogation to the Initial Enforcement Order of 1 April 2016 (the **Initial Order**). The terms defined in the Initial Order have the same meaning in this letter.

Under the Initial Order, save for written consent by the CMA, McKesson UK Finance I Limited and McKesson Corporation (together **McKesson Corporation**) and AAH are required to hold separate the MASTA-Sangers business from the McKesson Corporation business and refrain from taking any action which might prejudice a reference under section 22 of the Act or impede the taking of any remedial action following such a reference. After due consideration of your request for a derogation from the Initial Order, based on the information received from you and in the particular circumstances of this case, AAH and McKesson Corporation may carry out the following actions, in respect of the specific paragraphs:

#### **Paragraphs 4(a) and 5(l) of the Initial Order**

The current term of MASTA's [redacted] policy with [redacted] is expiring. Renewals were previously managed by the seller's group. For the purpose of ensuring that MASTA employees continue to benefit from their [redacted] policy, the CMA authorises the renewal by Celesio of the policy for the benefit of MASTA employees. In order to facilitate the renewal, the CMA authorises [redacted], and [redacted], employees within Celesio UK, as well as [redacted], an employee of Celesio AG, to have access to the information strictly required to negotiate the renewal of the contract (ie risk profile and claims history), providing that the information [redacted], [redacted] and [redacted] would have access to, will not be disclosed to any other individual carrying out activities within the McKesson Corporation and/or its subsidiaries. In order to comply with this requirement [redacted], [redacted] and [redacted] will sign a non-disclosure agreement (NDA) in a form approved by the CMA.